When Does Parkinson's Disease Begin?

被引:118
作者
Gaig, Carles [1 ]
Tolosa, Eduardo [1 ]
机构
[1] Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Neurodegnerat, Inst Clin Neurociencies, Neurol Serv,Parkinsons Dis & Movement Disorders U, Barcelona, Spain
关键词
Parkinson's disease; subclinical period; premotor phase; non-motor symptoms; pathology; neuroimaging; SLEEP BEHAVIOR DISORDER; ALPHA-SYNUCLEIN PATHOLOGY; CARDIAC SYMPATHETIC DENERVATION; POSITRON-EMISSION-TOMOGRAPHY; LEWY BODY DISEASE; F-18 DOPA UPTAKE; OLFACTORY DYSFUNCTION; REM-SLEEP; NIGROSTRIATAL DEGENERATION; MICROGLIAL ACTIVATION;
D O I
10.1002/mds.22672
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Pathological and neuroimaging studies have shown that in Parkinson's disease (PD) there is a "sub-clinical" or "premotor" period during which dopaminergic neurons in the substantia nigra (SN) degenerate but typical motor symptoms have not yet developed. Post-mortem studies based on nigral cell counts and evaluating dopamine levels in the striata, and imaging studies assessing the nigrostriatal pathway in vivo, have estimated that this time period could last 3 to 6 years. In addition, emerging evidence indicates that the neuropathological process of PD does not start in the SN but more likely elsewhere in the nervous system: in the lower brainstem and the olfactory bulb, or even more distant from the SN, such as in the peripheral autonomic nervous system. Patients with PD frequently can present non-motor symptoms, such as hyposmia or constipation, years before the development of classical motor signs. The physiopathology of these "premotor" symptoms, though still unclear, is currently thought to be related to early involvement by the pathological process underlying PD of non-dopaminergic lower brainstem structures or autonomic plexuses. However, the answer to the question "when does PD start" remains uncertain. Here, we review clinical, pathological, and neuroimaging data related to the onset of the pathological process of PD, and propose that its onset is non-motor and that non-motor symptoms could begin in many instances 10 and 20 years before onset of motor symptoms. The variable course of the disorder once the motor symptoms develop, suggests that the start and progression of premotor PD is also highly variable and given the heterogeneous nature of PD, may differ depending on the cause/s of the syndrome. When and where the neuropathological process develops in PD remains uncertain. (c) 2009 Movement Disorder Society
引用
收藏
页码:S656 / S664
页数:9
相关论文
共 96 条
[1]   Frequency of bowel movements and the future risk of Parkinson's disease [J].
Abbott, RD ;
Petrovitch, H ;
White, LR ;
Masaki, KH ;
Tanner, CM ;
Curb, JD ;
Grandinetti, A ;
Blanchette, PL ;
Popper, JS ;
Ross, GW .
NEUROLOGY, 2001, 57 (03) :456-462
[2]   PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation [J].
Adams, JR ;
van Netten, H ;
Schulzer, M ;
Mak, E ;
Mckenzie, J ;
Strongosky, A ;
Sossi, V ;
Ruth, TJ ;
Lee, CS ;
Farrer, M ;
Gasser, T ;
Uitti, RJ ;
Calne, DB ;
Wszolek, ZK ;
Stoessl, AJ .
BRAIN, 2005, 128 :2777-2785
[3]  
Asenbaum S, 1997, J NUCL MED, V38, P1
[4]   Constipation in Parkinson's disease: Objective assessment and response to psyllium [J].
Ashraf, W ;
Pfeiffer, RF ;
Park, F ;
Lof, J ;
Quigley, EMM .
MOVEMENT DISORDERS, 1997, 12 (06) :946-951
[5]  
Awerbuch G I, 1994, Int J Neurosci, V74, P9
[6]  
BAROLIN G. S., 1964, SCHWEIZ ARCH NEUROL NEUROCHIR PSYCHIAT ARCH SUISSES NEUROL NEUROCHIR PSYCHIAT ARCH SVIZZERO NEUROL NEUROCHIR PSICHIAT, V94, P241
[7]   Reduced striatal tyrosine hydroxylase in incidental Lewy body disease [J].
Beach, Thomas Gerald ;
Adler, Charles H. ;
Sue, Lucia I. ;
Peirce, JeVrey B. ;
Bachalakuri, Jyothi ;
Dalsing-Hernandez, Jessica E. ;
Lue, Lih Fen ;
Caviness, John N. ;
Connor, Donald J. ;
Sabbagh, Marwan N. ;
Walker, Douglas G. .
ACTA NEUROPATHOLOGICA, 2008, 115 (04) :445-451
[8]  
BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5
[9]   Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease [J].
Bezard, E ;
Dovero, S ;
Prunier, C ;
Ravenscroft, P ;
Chalon, S ;
Guilloteau, D ;
Crossman, AR ;
Bioulac, B ;
Brotchie, JM ;
Gross, CE .
JOURNAL OF NEUROSCIENCE, 2001, 21 (17) :6853-6861
[10]   α-Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects [J].
Bloch, A ;
Probst, A ;
Bissig, H ;
Adams, H ;
Tolnay, M .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2006, 32 (03) :284-295